These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

169 related items for PubMed ID: 17386188

  • 1. [Pulmonary hypertension treatment: future prospects].
    Baloira A.
    Arch Bronconeumol; 2007 Mar; 43(3):131-5. PubMed ID: 17386188
    [No Abstract] [Full Text] [Related]

  • 2. Clinical and cost-effectiveness of epoprostenol, iloprost, bosentan, sitaxentan and sildenafil for pulmonary arterial hypertension within their licensed indications: a systematic review and economic evaluation.
    Chen YF, Jowett S, Barton P, Malottki K, Hyde C, Gibbs JS, Pepke-Zaba J, Fry-Smith A, Roberts J, Moore D.
    Health Technol Assess; 2009 Oct; 13(49):1-320. PubMed ID: 19863849
    [Abstract] [Full Text] [Related]

  • 3. An evidence-based approach to the management of pulmonary arterial hypertension.
    Archer SL, Michelakis ED.
    Curr Opin Cardiol; 2006 Jul; 21(4):385-92. PubMed ID: 16755209
    [Abstract] [Full Text] [Related]

  • 4. Long-term follow-up after conversion from intravenous epoprostenol to oral therapy with bosentan or sildenafil in 13 patients with pulmonary arterial hypertension.
    Johnson RF, Loyd JE, Mullican AL, Fink CA, Robbins IM.
    J Heart Lung Transplant; 2007 Apr; 26(4):363-9. PubMed ID: 17403478
    [Abstract] [Full Text] [Related]

  • 5. Successful up-front combination therapy in a patient with idiopathic pulmonary hypertension and patent foramen ovale: an alternative to epoprostenol therapy?
    Pitsiou GG, Chavouzis N, Nakou C, Boutou AK, Argyropoulou P, Stanopoulos I.
    J Heart Lung Transplant; 2009 Jun; 28(6):651-3. PubMed ID: 19481029
    [Abstract] [Full Text] [Related]

  • 6. [The treatment of idiopathic pulmonary artery hypertension and its relation to systemic scleroderma].
    Humbert M.
    Rev Med Interne; 2007 Dec; 28 Suppl 4():S273-6. PubMed ID: 17961866
    [No Abstract] [Full Text] [Related]

  • 7. Bosentan and sildenafil: should the combination therapy be a valid alternative in childhood to prostacyclin infusion?
    Brancaccio G, Toscano A, Bevilacqua M, Di Chiara L, Parisi F.
    Pediatr Transplant; 2007 Feb; 11(1):110-2. PubMed ID: 17239133
    [Abstract] [Full Text] [Related]

  • 8. "Treat-to-target" in pulmonary arterial hypertension and the use of extracorporeal membrane oxygenation as a bridge to transplantation.
    Hoeper MM.
    Eur Respir Rev; 2011 Dec; 20(122):297-300. PubMed ID: 22130824
    [No Abstract] [Full Text] [Related]

  • 9. [Pulmonary arterial hypertension and systemic sclerosis].
    Launay D, Humbert M, Hachulla E.
    Presse Med; 2006 Dec; 35(12 Pt 2):1929-37. PubMed ID: 17159719
    [Abstract] [Full Text] [Related]

  • 10. Treatment of severe pulmonary hypertension secondary to scleroderma: a three-drug approach.
    Catapano-Minotti G, Corsonello A, Guadalupi G, Spani R, Antonelli-Incalzi R.
    Intern Med; 2008 Dec; 47(6):511-3. PubMed ID: 18344637
    [Abstract] [Full Text] [Related]

  • 11. An evidence-based approach to the management of pulmonary arterial hypertension.
    Coyne TC.
    Curr Opin Cardiol; 2006 Sep; 21(5):526; author reply 526-7. PubMed ID: 16900019
    [No Abstract] [Full Text] [Related]

  • 12. Combination drug therapy in the management of pulmonary arterial hypertension.
    Kayser SR.
    Prog Cardiovasc Nurs; 2005 Sep; 20(4):177-82. PubMed ID: 16276142
    [No Abstract] [Full Text] [Related]

  • 13. Relation of bosentan, iloprost, and sildenafil with growth factor levels in monocrotaline-induced pulmonary hypertension.
    Yigitaslan S, Sirmagul B.
    Clin Exp Hypertens; 2012 Sep; 34(3):222-9. PubMed ID: 22468718
    [Abstract] [Full Text] [Related]

  • 14. Portopulmonary hypertension.
    Nayak RP, Li D, Matuschak GM.
    Curr Gastroenterol Rep; 2009 Feb; 11(1):56-63. PubMed ID: 19166660
    [Abstract] [Full Text] [Related]

  • 15. Bosentan for the treatment of portopulmonary hypertension.
    Tempe DK, Datt V, Datta D.
    Ann Card Anaesth; 2008 Feb; 11(2):139-40; author reply 140. PubMed ID: 18603763
    [No Abstract] [Full Text] [Related]

  • 16. Pulmonary arterial hypertension: combination therapy in the modern management era.
    Sitbon O.
    Eur Respir Rev; 2010 Dec; 19(118):348-9. PubMed ID: 21119195
    [No Abstract] [Full Text] [Related]

  • 17. Treatment of pulmonary arterial hypertension.
    Humbert M, Sitbon O, Simonneau G.
    N Engl J Med; 2004 Sep 30; 351(14):1425-36. PubMed ID: 15459304
    [No Abstract] [Full Text] [Related]

  • 18. [Drug combination treatment for pulmonary arterial hypertension].
    Ghofrani HA, Hoeper MM.
    Dtsch Med Wochenschr; 2006 Dec 08; 131(49 Suppl 9):S330-3. PubMed ID: 17139600
    [Abstract] [Full Text] [Related]

  • 19. [Pharmacological treatment of pulmonary hypertension at a turning point].
    Watanabe H.
    Nihon Yakurigaku Zasshi; 2014 Apr 08; 143(4):165-72. PubMed ID: 24717603
    [No Abstract] [Full Text] [Related]

  • 20. Hemodynamics in pulmonary arterial hypertension (PAH): do they explain long-term clinical outcomes with PAH-specific therapy?
    Steele P, Strange G, Wlodarczyk J, Dalton B, Stewart S, Gabbay E, Keogh A.
    BMC Cardiovasc Disord; 2010 Feb 22; 10():9. PubMed ID: 20170553
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.